EyePoint (EYPT) Interest Expenses (2011 - 2026)
EyePoint (EYPT) posted Interest Expenses of $32.9 million for Q1 2026, up 1332.32% sequentially from -$2.7 million in Q4 2025, and up 846.33% YoY from $3.5 million in Q1 2025.
EyePoint (EYPT) Interest Expenses (2011 - 2026) Analysis & Trends
EyePoint has reported Interest Expenses for 16 years, with the latest figure at $32.9 million in Q1 2026.
- Quarterly Interest Expenses rose 846.33% year-over-year to $32.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.9 million (up 846.33% YoY) and the FY2025 annual result came in at $73.2 million, up 878.44% from the prior year.
- Interest Expenses climbed to $32.9 million in Q1 2026 per EYPT's latest filing, from -$2.7 million in the prior quarter.
- Over five years, Interest Expenses peaked at $72.4 million in Q2 2022 and troughed at -$2.7 million in Q4 2025.
- A 5-year average of $27.0 million and a median of $12.3 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 7872.91% in 2024, then plunged 481.0% in 2025.
- Over 5 years, Interest Expenses stood at $693000.0 in 2022, then retreated by 6.64% to $647000.0 in 2023, then climbed by 8.19% to $700000.0 in 2024, then slumped by 481.0% to -$2.7 million in 2025, then jumped by 1332.32% to $32.9 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $32.9 million, -$2.7 million, and $45.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 42.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.76 Mn |
| Jun 30, 2026 | 42.76 Mn |
| Mar 31, 2026 | 32.87 Mn |
| Mar 31, 2026 | 32.87 Mn |
| Dec 31, 2025 | -2.67 Mn |
| Dec 31, 2025 | -2.67 Mn |
| Sep 30, 2025 | 45.50 Mn |
| Sep 30, 2025 | 45.50 Mn |
| Jun 30, 2025 | 46.59 Mn |
| Jun 30, 2025 | 46.59 Mn |
| Mar 31, 2025 | 3.47 Mn |
| Mar 31, 2025 | 3.47 Mn |
| Dec 31, 2024 | 700,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 47.75 Mn |
| Sep 30, 2024 | 47.75 Mn |
| Jun 30, 2024 | 48.60 Mn |
| Jun 30, 2024 | 48.60 Mn |
| Mar 31, 2024 | 64.74 Mn |
| Mar 31, 2024 | 64.74 Mn |